Milestone Pharmaceuticals Inc. (MIST) — Financial statements
Income statement, balance sheet, and cash flow for Milestone Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2 | 0.00↓100.0% | 1↓80.0% | 5↓66.7% | 15 | |
| Cost of Revenue | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 1 | 0.00↓100.0% | 1↓80.0% | 5↓66.7% | 15 | |
| Operating Expenses | ||||||
| R&D Expenses | 18↑26.1% | 14↓53.8% | 31↓22.0% | 40↑3.0% | 39 | |
| General & Administrative Expenses | 17↑3.2% | 17↑5.1% | 16↑1.4% | 16↑26.8% | 12 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 11↓27.2% | 15↑66.2% | 9↑29.9% | 7 | |
| SG&A Expenses | 17↓37.7% | 28↓10.6% | 31↑25.1% | 25↑27.9% | 19 | |
| Other Expenses | 29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 64↑51.8% | 42↓32.2% | 62↓3.9% | 65↑11.3% | 58 | |
| Total Costs & Expenses | 64↑52.1% | 42↓32.2% | 62↓3.9% | 65↑11.3% | 58 | |
| Operating Results | ||||||
| Operating Income | -62↓48.4% | -42↑31.1% | -61↓2.4% | -60↓38.5% | -43 | |
| Depreciation & Amortization | 0.11↑8.6% | 0.11↑14.1% | 0.09↑3.4% | 0.09↓4.3% | 0.09 | |
| EBITDA | -62↓64.2% | -38↑33.7% | -57↑2.2% | -58↓35.6% | -43 | |
| EBIT | -62↓64.7% | -38↑33.6% | -57↑2.2% | -58↓35.6% | -43 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.92↓111.9% | 8↑448.1% | 1↑12.7% | 1↑470.0% | 0.22 | |
| Interest Income | 3↓29.9% | 4↑5.0% | 4↑216.3% | 1↑470.0% | 0.22 | |
| Interest Expense | 4↑207.2% | -4↓240.2% | 3 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -4↓5.0% | -4↓216.3% | -1 | 0.00 | |
| Other Income / Expenses | -0.92↓257.5% | 0.58↓58.7% | 1↑12.7% | 1↑470.0% | 0.22 | |
| Income Before Tax | -63↓52.7% | -42↑30.4% | -60↓2.2% | -58↓36.3% | -43 | |
| Income Tax Expense | -0.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -63↓51.9% | -42↑30.4% | -60↓2.2% | -58↓36.3% | -43 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -63↓51.9% | -42↑30.4% | -60↓2.2% | -58↓36.3% | -43 | |
| Bottom-Line Net Income | -63↓51.9% | -42↑30.4% | -60↓2.2% | -58↓36.3% | -43 | |
| EPS (Basic) | -0.75↓11.9% | -0.67↑51.8% | -1.39↓3.0% | -1.35↓32.4% | -1.02 | |
| EPS (Diluted) | -0.75↓11.9% | -0.67↑51.8% | -1.39↓3.0% | -1.35↓32.4% | -1.02 | |
| Weighted Average Shares | 84↑34.8% | 62↑44.8% | 43↑1.2% | 42↑1.5% | 42 | |
| Weighted Average Diluted Shares | 84↑34.8% | 62↑44.8% | 43↑1.2% | 42↑1.5% | 42 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.